Background-Haemochromatosis is associated with mutations in the HFE gene but the significance of these mutations in the general population is unknown. Aims-To determine the frequency of HFE gene mutations in the general population, their eVect on serum iron indexes, and their role in screening for haemochromatosis. Methods-Deoxyribonucleic acid (DNA) from 1064 randomly selected subjects was analysed for the C282Y and H63D mutations in the HFE gene. Serum iron, transferrin saturation, and ferritin were measured and individuals with increased iron indexes were investigated to confirm or exclude a clinical diagnosis of haemochromatosis. Results-Mutations were identified in 409 individuals (38.4%) with heterozygote (carrier) frequencies of 13.2% and 24.3% for the C282Y and H63D mutations respectively. Heterozygosity for either mutation significantly increased serum iron and transferrin saturation but despite a similar trend for ferritin, this was only significant for C282Y homozygotes. Five individuals (0.47%) were homozygous for the C282Y mutation, three of whom had haemochromatosis confirmed by liver biopsy (0.28%). The other two C282Y homozygotes would not have been detected by phenotypic screening alone. Conclusions-HFE mutations are present in 38.4% of the population, aVect serum iron indexes, and are important determinants of iron status. The population frequency of genetically defined haemochromatosis (C282Y homozygosity) is approximately one in 200 and is higher than the prevalence of clinically apparent haemochromatosis. (Gut 1998;43:830-836) 
Haemochromatosis is a common autosomal recessive disorder of iron metabolism occurring with a prevalence of 0.2 to 0.5% in Caucasian populations. 1−6 It is characterised by the excessive absorption of dietary iron and a progressive rise in body iron stores which may result in cirrhosis, diabetes, cardiac failure and arrhythmias, hypogonadism, arthritis, hepatocellular carcinoma, and reduced life expectancy. 7 8 The morbidity and mortality of haemochromatosis can be reduced by venesection to remove the iron burden, 9 and early diagnosis is important as the life expectancy of treated non-cirrhotic patients is normal. 10−12 The diagnosis of haemochromatosis has traditionally relied on the demonstration of increased iron stores and the exclusion of secondary iron overload. Diagnosis is therefore dependent on phenotypic expression but this is related to age and can be modified by non-genetic factors such as dietary composition, blood donation, menstruation, pregnancy, and pathological blood loss. 7 The recent identification of the haemochromatosis gene has important implications for diagnosis and screening. 13 Originally termed HLA-H, now designated HFE, 14 the gene encodes a 343 amino acid protein with homology to major histocompatibility class I molecules. 13 Two missense mutations have been identified in this gene. The first causes a substitution of cysteine with a tyrosine residue at position 282 (C282Y) and homozygosity for this mutation has been identified in 64-100% of reported patients. 13 15−18 The significance of the second mutation, a substitution of histidine with aspartate at position 63 (H63D), is controversial. 19 Although homozygosity for this mutation is not clearly associated with haemochromatosis, some patients are compound heterozygotes, that is, heterozygous for both the C282Y and H63D mutation. 13 16−20 The aims of this study were to determine the frequency of the two HFE gene mutations in a large random population sample, to determine their eVect on serum iron indexes, and to evaluate their use in screening for haemochromatosis.
Methods

SUBJECTS
The study was designed to obtain a random sample of 1000 subjects representative of the adult population of Christchurch, New Zealand, a city with a predominantly European population of 350 000. A list of 4000 names was randomly generated from the 1996 electoral rolls (approximately 93% of the population over 18 years of age are enrolled voters) and was used to recruit subjects sequentially. Subjects were contacted by telephone and invited to participate by a trained interviewer. If subjects declined to participate, limited demographic data were requested and recorded if given. If subjects were not able to be contacted by telephone they were sent an information sheet and asked to contact an interviewer. Volunteers attended Christchurch Hospital, completed a questionnaire, and provided a fasting blood specimen. Subjects unable to come to the hospital were visited at home. Informed consent was obtained from all subjects and the study protocol was approved by the Southern Regional Health Authority's Ethics Committee.
In total 3510 adults were invited to participate: 2032 (57.9%) by telephone and 1478 (42.1%) by letter. Final enrolment was 1064 (30.3% of the 3510 subjects approached) and included 52 individuals who were visited at home. A greater proportion of subjects initially contacted by telephone (42.3%) participated in the study compared with those contacted by letter (13.8%). The reasons for nonparticipation (n=2446) were: not able to be contacted (errors in the electoral roll or change of address) in 112 (4.6%); refusal in 744 (30.4%); initial agreement but failure to attend in 357 (14.6%); and no response to a letter of invitation in 1233 (50.4%). When available, information on sex and employment status was extracted from the electoral rolls and analysis indicated that the study sample contained a higher proportion of females and retirees, and proportionately fewer students and unemployed subjects compared with those who did not participate in the study (table 1) . Age and racial background are not available from the electoral rolls but were supplied by more than 90% of the 735 subjects who were contacted by telephone but declined to participate, and were not significantly diVerent from the study population (table 1) .
Fasting blood samples were collected from all 1064 study participants. Subjects with a transferrin saturation of greater than 55% were asked to provide a further fasting blood specimen for repeat iron analyses. Those subjects with a consistently elevated transferrin saturation and a consistently elevated serum ferritin concentration (males greater than 300 µg/l, females greater than 160 µg/l) were reviewed and oVered liver biopsy. Biopsy specimens were stained with Perls' Prussian blue and the stainable iron was graded 0-4. 21 The hepatic iron concentration was determined by atomic absorption spectrophotometry and hepatic iron index (µmol iron/g dry tissue/year) was calculated. 22 23 A hepatic iron index greater than 2.0 is consistent with homozygous haemochromatosis. 22 All patients homozygous for the C282Y mutation were reviewed and liver biopsy was performed if their iron indexes met the above criteria.
SERUM IRON INDEXES
Serum was separated and stored at −20°C until analysis. The serum iron concentration, unbound iron binding capacity, and serum ferritin concentration were all measured simultaneously on a Hitachi 717 analyser (Boehringer Mannheim, Indianapolis, Indiana) according to the manufacturer's instructions using reagents supplied by Boehringer. Iron and unbound iron binding capacity were measured using FerroZine (no. 1553712) and added together to determine the total iron binding capacity. Iron was divided by the total iron binding capacity and multiplied by 100 to calculate the percentage saturation (transferrin saturation). Ferritin was measured using latex bound antibodies (Tina-quant Ferritin no. 1661400) and calibrated with Preciset Ferritin (no. 1056689). The manufacturer's stated reference ranges for serum ferritin (males 30-300 µg/l, females 10-160 µg/l) were used to define iron deficiency and possible iron overload.
ANALYSIS OF HFE GENE MUTATIONS
DNA was extracted from peripheral blood 24 and stored at −20°C for analysis of the HFE gene. The C282Y mutation creates an Rsa I restriction site and the H63D mutation abolishes a Bcl I site allowing detection of the two mutations by polymerase chain reaction (PCR) amplification and restriction enzyme digestion. 25 Primer sequences were those described by Feder et al. 13 PCR was performed in 50 µl reactions containing 12.5 pmol of each primer, 200 µmol/l deoxynucleoside triphosphates, 1.5 mmol/l MgCl 2 , 0.5 U Taq polymerase, and 5 µl of the DNA preparation. The products were digested by addition of restriction enzyme and analysed by electrophoresis in 4% agarose gels.
STATISTICAL ANALYSIS
Demographic parameters were compared between the study population and the nonparticipants, and between genotype groups using 2 or t tests as appropriate. The proportion of iron deficient individuals in each genotype was compared using 2 tests or Fisher's exact test when expected frequencies were low. The eVect of genotype and sex on iron indexes was assessed using analysis of variance (ANOVA) and when this was significant for genotype, pairwise comparisons between genotypes were made using Fisher's least significant diVerence test. In the case of ferritin the data were log transformed prior to analysis to normalise the distribution. The eVect of genotype on ferritin concentrations was assessed after correction for both age and sex. All statistical tests were two sided.
Results
HFE GENOTYPES AND MUTATION FREQUENCIES
There were five subjects homozygous for the C282Y mutation (0.5%) and 140 C282Y heterozygotes (13.2%), 19 of whom were were also H63D heterozygotes (compound heterozygotes) (table 2) . Twenty four subjects (2.3%) were homozygous for the H63D mutation and 259 were heterozygous (24.3%) for this mutation either alone (n=240) or as compound heterozygotes (n=19). The gene frequency of the C282Y mutation in this population was therefore 0.070; it was 0.144 for the H63D mutation.
In total 38.4% of the study population carried one or more HFE gene mutations. There were no significant diVerences in genotype frequencies between males and females or between groups with diVerent employment status. The study sample was composed predominantly of Europeans (New Zealand born European 92.9%, European migrants 3.1%) and there were only 43 non-European subjects (23 Maoris, eight Pacific Islanders, five Asians, three Indians, four others). Mutations were present in seven non-Europeans (one C282Y heterozygote, six H63D heterozygotes), a prevalence of 16.3% compared with 39.4% in Europeans. However, this diVerence was only significant for the C282Y mutation (p=0.002). Table 2 summarises the serum iron indexes for each genotype. The mean serum iron concentration, transferrin saturation, and serum ferritin concentration were significantly lower in women. There were, however, no significant interactions between sex and genotype for these indexes. This implies that the diVerences between the sexes were consistent in all genotype groups. All five genotype groups with a mutation had higher mean serum iron concentrations, lower mean total iron binding capacities, and higher mean transferrin saturations than the 655 subjects with no mutations. Although a similar trend was apparent for mean serum ferritin concentrations, this only reached statistical significance for C282Y homozygotes. When compared with simple C282Y heterozygotes, compound heterozygotes had significantly higher mean serum iron and transferrin saturations but the diVerence in mean serum ferritin concentrations was not significant.
HFE GENOTYPE AND IRON INDEXES
Elevated serum iron indexes have been reported in 10-30% of heterozygotes identified by HLA typing in family studies; however, the HFE genotype of these individuals is unknown. 26−30 In order to determine the proportion of genotyped heterozygotes with elevated iron indexes compared with individuals with a normal genotype, we defined the upper limit of the normal range, for transferrin saturation and serum ferritin, from the 655 subjects without a mutation (a genotype specific range). 26 For transferrin saturation this was defined as the mean plus two standard deviations and was 50.5%. Elevated values were observed in 16 of the 140 C282Y heterozygotes (11.4%) (table 3). A significantly higher proportion of compound heterozygotes (26.3%) had an elevated transferrin saturation compared with simple C282Y heterozygotes (9.1%, p=0.028). For ferritin the upper limit of normal was defined as the 97.5th percentile of the 655 subjects without a mutation and was 428 µg/l for males and 302 µg/l for females. 26 Fourteen of the 140 C282Y heterozygotes (10%) had serum ferritin concentrations exceeding these limits (table 3) but unlike transferrin saturation there were no significant diVerences between compound and simple C282Y heterozygotes.
A total of 52 subjects (4.9%) were iron deficient as defined by a serum ferritin concentration less than 30 µg/l for males (n=24) and less There were 39 subjects (3.7%) with an initial transferrin saturation greater than 55% (fig 1) . Mutations in the HFE gene were present in 28 of the 39 subjects (71.2%) and included all genotypes except compound heterozygosity. Further analysis indicated that the C282Y mutation (p<0.001) but not the H63D mutation (p=0.27) was significantly more common in those with a transferrin saturation greater than 55%. Transferrin saturation remained elevated in 13 of the 38 subjects who had repeat fasting iron measurements (fig 1) . In eight subjects this was associated with a persistently elevated serum ferritin concentration (males >300 µg/l, females >160 µg/l) and these subjects all underwent liver biopsy. Histology and hepatic iron indexes were consistent with haemochromatosis in three cases, all of whom were C282Y homozygotes; these subjects were discussed above. Biopsy results did not support a diagnosis of haemochromatosis in the other five patients with stainable iron graded 0-2 and hepatic iron indexes of between 0.4 and 1.2 µmol/g dry tissue/year. Thus, the prevalence of clinically apparent haemochromatosis based on the liver biopsy findings of subjects with persistently elevated transferrin saturation and serum ferritin concentration was one in 355 (0.28%). The five patients with elevated transferrin saturations but without consistently elevated serum ferritin concentrations were not biopsied but this group included two C282Y homozygotes (fig 1) .
Discussion
Haemochromatosis has increasingly been recognised as a common disorder but previous estimates of its prevalence have been based on phenotypic expression of the disease. In this study we have established the frequency of HFE gene mutations and analysed their relation to serum iron indexes and to clinically significant iron overload. The C282Y and H63D mutations occurred at gene frequencies of 0.070 and 0.144 respectively. Heterozygosity for the C282Y and H63D mutations was present in 13.2% and 24.3% of the study population respectively and nearly two fifths (38.4%) of the study population carried one or more HFE gene mutations.
Although every attempt was made to obtain a random sample, the study population was not completely representative of the target population with sex and employment status aVecting participation. There were, however, no significant sex or occupational diVerences in HFE genotype frequencies and it is therefore unlikely that these recruitment diVerences significantly aVected the observed mutation frequencies. No patients with previously diagnosed haemochromatosis were recruited but eight subjects had a family history of the disorder, two of whom were found to be C282Y homozygotes, two were C282Y heterozygotes, and the remaining four had no HFE gene mutations. These subjects may have been more likely to volunteer for the study but this would have a minimal eVect on the estimated gene frequency as they represent only six (4%) of the 150 chromosomes aVected by C282Y mutations detected in the study population. Furthermore, the prevalence of C282Y homozygosity predicted from the gene frequency (1:201) is very close to the observed prevalence of 1:213 and to that reported in Australian and British populations. 31 32 Haemochromatosis predominantly aVects Caucasians of European descent, 3 4 7 32 33 and may have arisen in an ancient Celtic population with subsequent migration explaining the geographical distribution of the disorder. 32 The New Zealand population is predominantly of British-Irish ancestry and the observed genotype frequencies are very similar to those reported in a recent study of 413 British subjects. 32 It has been suggested that the relatively high prevalence of haemochromatosis in populations of Celtic descent may reflect a selective advantage protecting heterozygotes from iron deficiency when dietary iron intake is limited. 34−36 Two studies have shown that low serum ferritin concentrations are less common in heterozygous women compared with controls. 30 37 In contrast to these studies, which assigned probable genotype by HLA typing, we did not find any significant diVerences in HFE genotype distribution between iron deficient and iron replete subjects, even when the analysis was restricted to women in the reproductive age range. However, it is possible that any effect is masked in New Zealand where meat intake is high and iron supplementation during pregnancy is common.
There is, however, clear evidence that HFE mutations aVect serum iron indexes and subjects with one or more mutations had significantly higher mean serum iron concentrations and transferrin saturations compared with normal subjects. Serum ferritin concentrations were also consistently higher but this was only significant for C282Y homozygotes. Approximately 10% of C282Y heterozygotes had elevated transferrin saturations or serum ferritin concentrations above the upper limit of normal as determined from individuals without any HFE mutations. This supports and extends earlier observations of partial biochemical expression in a proportion of heterozygotes ascertained in family studies. 26−30 The HFE gene was identified by positional cloning and it is probable that HFE mutations are the underlying cause of most cases of haemochromatosis. 38 In all series reported to date the majority of cases have been homozygous for the C282Y mutation. 13 15−18 All three biopsy confirmed cases of haemochromatosis in this study were C282Y homozygotes giving a prevalence of 1 in 355 (0.28%). A fourth C282Y homozygote is almost certainly affected but did not have an elevated serum ferritin and was not biopsied. The fifth subject has a normal serum ferritin possibly related to her age and poor diet, although an unidentified malabsorption disorder cannot be excluded. The number of homozygous subjects who will develop clinical disease is unknown. 39 It has previously been shown that nearly all individuals identified as putative homozygotes by HLA typing will develop evidence of iron overload in the absence of an environmental or genetic modifying factor. 40 However, a recent Australian study has reported that 17.3% of subjects homozygous for the C282Y mutation do not express iron overload suYcient to meet current diagnostic criteria of haemochromatosis. 41 Our study confirms that haemochromatosis is a common condition aVecting populations of European descent and that approximately 1 in 200 of this population carry a genotype that places them at a high lifetime risk for the development of iron overload. However, two of the five C282Y homozygotes in this study would not have been detected by screening protocols based on serum iron indexes alone.
The significance of the H63D mutation has been controversial and it has been suggested that this is simply a genetic polymorphism. 16 18 We found that individuals either homozygous or heterozygous for the H63D mutation had significantly higher mean serum iron concentrations and transferrin saturations compared with subjects with no HFE gene mutations. Higher serum ferritin concentrations were observed but this did not reach statistical significance. Similar trends were observed when comparing compound heterozygotes with simple C282Y heterozygotes. Despite this we did not find a significant clinical eVect of the H63D mutation. This mutation did not confer protection from iron deficiency, it did not increase the prevalence of a transferrin saturation greater than 55%, and no subject had iron overload.
However, the high frequency and eVects of both the C282Y and H63D mutations suggest that these two mutations are important determinants of the iron status of populations of European descent. Iron status may be important in other diseases and associations with ischaemic heart disease 42 and the response of hepatitis C to interferon have been reported. 43 Further study is required to determine the significance of HFE gene mutations in these situations as currently the only confirmed associations are those between the C282Y mutation and porphyria cutanea tarda 44 and nonalcoholic steatohepatitis. 45 Haemochromatosis is an attractive candidate for large scale population based screening programmes. 46−48 It is common and causes significant morbidity; yet there is a simple and eVective treatment that alters the natural history of the disease and preserves life expectancy in precirrhotic individuals. 9 12 49 The current screening test of choice is transferrin saturation. 49 We adopted a screening strategy 2 based on a transferrin saturation cut oV value of 55% and established the diagnosis by liver biopsy in subjects with a persistently elevated transferrin saturation and serum ferritin concentration. This identified three individuals with haemochromatosis, all of whom were C282Y homozygotes. An alternate screening strategy based on HFE mutation analysis of either the entire study population or just those individuals with an elevated transferrin saturation, would have identified all three confirmed cases together with an additional two C282Y homozygotes who may subsequently develop overt iron overload. Screening using DNA analysis has the advantage of detecting subjects with delayed or incomplete phenotypic expression, allowing diagnosis at an early age and treatment to prevent clinically significant iron overload. However, there are potential problems with the widespread introduction of molecular screening. Firstly, in some populations the number of haemochromatosis patients without HFE gene mutations is significant. 18 Secondly, until the cost of genotyping can be reduced transferrin saturation will remain the most cost eVective screening test. At the moment screening programmes should probably restrict genotyping to those individuals with an elevated transferrin saturation although mutation analysis may well become the screening test of choice in the future.
